vs
Side-by-side financial comparison of Cue Biopharma, Inc. (CUE) and Ponce Financial Group, Inc. (PDLB). Click either name above to swap in a different company.
Ponce Financial Group, Inc. is the larger business by last-quarter revenue ($31.4M vs $21.9M, roughly 1.4× Cue Biopharma, Inc.). Ponce Financial Group, Inc. runs the higher net margin — 36.3% vs 7.2%, a 29.1% gap on every dollar of revenue. On growth, Cue Biopharma, Inc. posted the faster year-over-year revenue change (1292.3% vs 37.6%). Over the past eight quarters, Cue Biopharma, Inc.'s revenue compounded faster (257.5% CAGR vs 23.7%).
Cue Biopharma is a clinical-stage biotechnology company focused on developing novel targeted immunotherapies for cancer, autoimmune disorders, and inflammatory diseases. Its proprietary platform enables precise T-cell activity modulation, with core operations in North America and global pharma partnerships to advance lead product candidates through clinical trials.
Ponce Financial Group, Inc. is a U.S.-based financial holding company operating Ponce Bank as its core subsidiary. It serves multicultural, immigrant and low-to-moderate income communities in the New York metro area, offering retail and commercial banking products including deposits, mortgages, small business financing and personal credit.
CUE vs PDLB — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $21.9M | $31.4M |
| Net Profit | $1.6M | $10.1M |
| Gross Margin | — | — |
| Operating Margin | 9.0% | 43.6% |
| Net Margin | 7.2% | 36.3% |
| Revenue YoY | 1292.3% | 37.6% |
| Net Profit YoY | 116.7% | 245.6% |
| EPS (diluted) | $0.05 | $0.43 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $21.9M | $31.4M | ||
| Q3 25 | $2.1M | $26.7M | ||
| Q2 25 | $3.0M | $26.5M | ||
| Q1 25 | $421.0K | $24.6M | ||
| Q4 24 | $1.6M | $22.8M | ||
| Q3 24 | $3.3M | $20.2M | ||
| Q2 24 | $2.7M | $20.2M | ||
| Q1 24 | $1.7M | $20.5M |
| Q4 25 | $1.6M | $10.1M | ||
| Q3 25 | $-7.4M | $6.5M | ||
| Q2 25 | $-8.5M | $6.1M | ||
| Q1 25 | $-12.3M | $6.0M | ||
| Q4 24 | — | $2.9M | ||
| Q3 24 | $-8.7M | $2.4M | ||
| Q2 24 | $-10.2M | $3.2M | ||
| Q1 24 | $-12.3M | $2.4M |
| Q4 25 | 9.0% | 43.6% | ||
| Q3 25 | -353.4% | 32.8% | ||
| Q2 25 | -292.3% | 30.2% | ||
| Q1 25 | -2921.4% | 32.5% | ||
| Q4 24 | — | 19.6% | ||
| Q3 24 | -264.2% | 15.2% | ||
| Q2 24 | -390.6% | 21.8% | ||
| Q1 24 | -737.8% | 18.3% |
| Q4 25 | 7.2% | 36.3% | ||
| Q3 25 | -346.6% | 24.3% | ||
| Q2 25 | -287.1% | 23.0% | ||
| Q1 25 | -2911.4% | 24.2% | ||
| Q4 24 | — | 14.1% | ||
| Q3 24 | -259.6% | 12.1% | ||
| Q2 24 | -382.7% | 15.8% | ||
| Q1 24 | -719.1% | 11.8% |
| Q4 25 | $0.05 | $0.43 | ||
| Q3 25 | $-0.07 | $0.27 | ||
| Q2 25 | $-0.09 | $0.25 | ||
| Q1 25 | $-0.17 | $0.25 | ||
| Q4 24 | — | $0.11 | ||
| Q3 24 | $-0.17 | $0.10 | ||
| Q2 24 | $-0.20 | $0.14 | ||
| Q1 24 | $-0.25 | $0.11 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $27.1M | $126.2M |
| Total DebtLower is stronger | — | $596.1M |
| Stockholders' EquityBook value | $26.4M | $541.5M |
| Total Assets | $42.2M | $3.2B |
| Debt / EquityLower = less leverage | — | 1.10× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $27.1M | $126.2M | ||
| Q3 25 | $11.7M | $146.6M | ||
| Q2 25 | $27.5M | $126.6M | ||
| Q1 25 | $13.1M | $129.9M | ||
| Q4 24 | $22.5M | $139.8M | ||
| Q3 24 | $32.4M | $155.8M | ||
| Q2 24 | $30.0M | $103.2M | ||
| Q1 24 | $41.0M | $134.7M |
| Q4 25 | — | $596.1M | ||
| Q3 25 | — | $521.1M | ||
| Q2 25 | — | $536.1M | ||
| Q1 25 | — | $521.1M | ||
| Q4 24 | — | $596.1M | ||
| Q3 24 | $1.0M | $580.4M | ||
| Q2 24 | $2.0M | $680.4M | ||
| Q1 24 | $3.0M | $680.4M |
| Q4 25 | $26.4M | $541.5M | ||
| Q3 25 | $13.2M | $529.8M | ||
| Q2 25 | $18.2M | $521.1M | ||
| Q1 25 | $6.6M | $513.9M | ||
| Q4 24 | $17.5M | $505.5M | ||
| Q3 24 | $25.4M | $504.6M | ||
| Q2 24 | $21.6M | $497.7M | ||
| Q1 24 | $30.0M | $493.7M |
| Q4 25 | $42.2M | $3.2B | ||
| Q3 25 | $31.6M | $3.2B | ||
| Q2 25 | $40.7M | $3.2B | ||
| Q1 25 | $22.3M | $3.1B | ||
| Q4 24 | $32.2M | $3.0B | ||
| Q3 24 | $44.8M | $3.0B | ||
| Q2 24 | $42.3M | $2.8B | ||
| Q1 24 | $54.0M | $2.8B |
| Q4 25 | — | 1.10× | ||
| Q3 25 | — | 0.98× | ||
| Q2 25 | — | 1.03× | ||
| Q1 25 | — | 1.01× | ||
| Q4 24 | — | 1.18× | ||
| Q3 24 | 0.04× | 1.15× | ||
| Q2 24 | 0.09× | 1.37× | ||
| Q1 24 | 0.10× | 1.38× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.1M | $55.6M |
| Free Cash FlowOCF − Capex | — | $54.6M |
| FCF MarginFCF / Revenue | — | 173.9% |
| Capex IntensityCapex / Revenue | 0.0% | 3.1% |
| Cash ConversionOCF / Net Profit | -0.68× | 5.48× |
| TTM Free Cash FlowTrailing 4 quarters | — | $74.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-1.1M | $55.6M | ||
| Q3 25 | $-9.0M | $1.4M | ||
| Q2 25 | $-3.4M | $6.2M | ||
| Q1 25 | $-8.2M | $13.1M | ||
| Q4 24 | $-36.3M | $7.2M | ||
| Q3 24 | $-7.5M | $-14.6M | ||
| Q2 24 | $-10.0M | $-2.6M | ||
| Q1 24 | $-9.8M | $1.5M |
| Q4 25 | — | $54.6M | ||
| Q3 25 | — | $786.0K | ||
| Q2 25 | $-3.4M | $5.9M | ||
| Q1 25 | $-8.3M | $12.9M | ||
| Q4 24 | $-36.4M | $4.5M | ||
| Q3 24 | $-7.5M | $-15.0M | ||
| Q2 24 | $-10.0M | $-2.6M | ||
| Q1 24 | $-9.8M | $-315.0K |
| Q4 25 | — | 173.9% | ||
| Q3 25 | — | 2.9% | ||
| Q2 25 | -116.5% | 22.4% | ||
| Q1 25 | -1976.7% | 52.6% | ||
| Q4 24 | -2309.3% | 19.7% | ||
| Q3 24 | -225.7% | -74.1% | ||
| Q2 24 | -376.2% | -13.0% | ||
| Q1 24 | -573.0% | -1.5% |
| Q4 25 | 0.0% | 3.1% | ||
| Q3 25 | 0.0% | 2.3% | ||
| Q2 25 | 0.9% | 1.0% | ||
| Q1 25 | 35.6% | 0.6% | ||
| Q4 24 | 4.2% | 11.9% | ||
| Q3 24 | 0.0% | 2.0% | ||
| Q2 24 | 0.4% | 0.3% | ||
| Q1 24 | 3.2% | 8.7% |
| Q4 25 | -0.68× | 5.48× | ||
| Q3 25 | — | 0.21× | ||
| Q2 25 | — | 1.01× | ||
| Q1 25 | — | 2.20× | ||
| Q4 24 | — | 2.46× | ||
| Q3 24 | — | -5.99× | ||
| Q2 24 | — | -0.80× | ||
| Q1 24 | — | 0.61× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CUE
| Immuno Scape Collaboration And License Agreement | $9.5M | 43% |
| BI Collaboration And License Agreement | $8.1M | 37% |
| Other | $4.3M | 20% |
PDLB
Segment breakdown not available.
